Headline Business Wire 2026-05-04T20:05:22Z

Seagate to Participate in Upcoming Investor Events

Permitted excerpt

Seagate Technology Holdings plc announced its participation in three upcoming investor events in May and June 2026: the J.P. Morgan Global Technology, Media and Communications Conference, the TD Cowen Annual Technology, Media and Telecom Conference, and the Bank of America Global Technology Conference. Management will host investor meetings, and webcasts of the presentations will be available on Seagate’s Investor Relations website.

To see the full article, use the original source link. To see the full article: see Business Wire.

STXtechnology

Stock Titan 2026-05-04T20:34:19Z

John Morris files Form 144 reporting STX sales (NASDAQ: STX)

John Morris filed a Form 144 detailing proposed sales of Seagate Technology Holdings plc (STX) common stock, along with recent 10b5-1 sales. The filing specifies dispositions tied to equity awards from 2024 and executed sales on February 24, 2026, and March 13, 2026. This SEC document provides transparency regarding insider trading plans and recent share...

Business Wire 2026-05-04T21:08:16Z

Bragg Gaming to Release First Quarter 2026 Results on May 14

Bragg Gaming Group will release its first quarter 2026 financial results on Thursday, May 14, 2026, before market open. This will be followed by a conference call at 8:30 a.m. Eastern Time, where CEO Matevž Mazij and CFO Robbie Bressler will discuss the results and provide a business update. The call details and a link to the webcast archive are provided...

Quantisnow 2026-05-04T21:05:07Z

Paycom Announces Quarterly Cash Dividend

Paycom Software Inc. has announced a quarterly cash dividend. This update was reported by Quantisnow, a platform that provides real-time market data and news for retail investors. The article also includes recent analyst ratings and related SEC filings and press releases concerning Paycom.

MarketBeat 2026-05-04T21:03:23Z

Julie Knecht Sells 9,956 Shares of Texas Instruments (NASDAQ:TXN) Stock

Julie Knecht, Chief Accounting Officer of Texas Instruments (NASDAQ:TXN), sold 9,956 shares of the company's stock on May 1st for a total of $2,774,737.20, significantly reducing her direct holdings. This transaction follows Texas Instruments' Q1 earnings report, where the company beat EPS estimates but slightly missed revenue expectations, and declared a...

MarketBeat 2026-05-04T21:03:20Z

Catherine Clay Acquires 2,500 Shares of S&P Global (NYSE:SPGI) Stock

Catherine Clay, CEO of S&P Global (NYSE:SPGI), recently acquired 2,500 shares of the company's stock for over $1 million, increasing her holdings. S&P Global reported strong quarterly earnings, surpassing analyst expectations with $4.97 EPS and $4.17 billion in revenue, and has issued optimistic FY2026 guidance. The stock maintains a "Buy" consensus rating...

MarketBeat 2026-05-04T21:02:59Z

BWX Technologies (NYSE:BWXT) Releases FY 2026 Earnings Guidance

BWX Technologies (NYSE:BWXT) has released its FY 2026 earnings guidance, projecting an EPS of $4.60-$4.75 and revenue of $3.8 billion, aligning with Street estimates. The company also announced an increase in its quarterly dividend to $0.27, resulting in an annualized yield of approximately 0.5%. Shares currently trade around $216.92, maintaining a...

Stock Titan 2026-05-04T20:58:57Z

Marathon Petroleum (MPC) director granted 727-share 2026 equity retainer

Marathon Petroleum Corp. director J. Michael Stice received an annual 2026 equity retainer award consisting of 727.742 common shares, as reported in a Form 4 SEC filing. These shares were granted at $0.0000 per share, indicating stock-based compensation. Following this award and dividend reinvestment, Stice now directly holds 24,721.254 Marathon Petroleum...

StockStory 2026-05-04T20:57:27Z

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations

Vertex Pharmaceuticals (NASDAQ:VRTX) exceeded Wall Street's revenue and earnings expectations for Q1 CY2026, with sales reaching $2.99 billion and non-GAAP EPS of $4.47. The company reaffirmed its full-year revenue guidance and highlighted strong performance in cystic fibrosis, sickle cell disease, beta-thalassemia, and acute pain, alongside pipeline...